ClinicalTrials.gg
CompletedNCT00929201Updated Aug 13, 2015Results posted

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

A Phase 1 interventional study of Sitagliptin phosphate/metformin hydrochloride FDC and Sitagliptin phosphate in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
123rd of 197
61 · median 102
Started
2008
with 22 others
Phase 1
23 of 198
none open now
Registered
70th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 123rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 70th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is in good health
  • is a nonsmoker
  • is willing to follow all study guidelines

Exclusion criteria

Exclusion Criteria:

  • has or has a history of any illness or condition that might confound the results of the study or make participation unsafe for the participant
  • is a nursing mother
  • is unwilling to consume the required high-fat breakfast
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Sita + Met then Sita/Met FDC

    Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.

    Drug: Sitagliptin phosphate/metformin hydrochloride FDC · Drug: Sitagliptin phosphate · Drug: Metformin hydrochloride

  • Active comparator
    Sita/Met FDC then Sita + Met

    Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.

    Drug: Sitagliptin phosphate/metformin hydrochloride FDC · Drug: Sitagliptin phosphate · Drug: Metformin hydrochloride

Interventions

  • DrugSitagliptin phosphate/metformin hydrochloride FDC

    Drug pages: Sitagliptin · Metformin

    Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.

  • Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.

  • Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.

06

What researchers measure

Primary outcomes

  1. Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin

    Serum samples were used to determine the AUC from time 0 to infinity for metformin.

    Time frame: Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of Metformin

    Serum samples were used to determine the maximum concentration for metformin.

    Time frame: Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose

07

Results

Posted Feb 1, 2010

Participant flow

Period 1
Participant flow — Period 1
MilestoneSita + Met Then Sita/Met FDCSita/Met FDC Then Sita + Met
Started3031
Completed3030
Not completed01
Withdrew: Withdrawal by subject01
7-day Washout
Participant flow — 7-day Washout
MilestoneSita + Met Then Sita/Met FDCSita/Met FDC Then Sita + Met
Started3030
Completed3030
Not completed00
Period 2
Participant flow — Period 2
MilestoneSita + Met Then Sita/Met FDCSita/Met FDC Then Sita + Met
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryPlasma Area Under the Curve (AUC(0 to Infinity)) for Metformin

Serum samples were used to determine the AUC from time 0 to infinity for metformin.

Time frame:
Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose
Reported as:
Least squares mean · μg * hr/mL
Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin
μg * hr/mLSita + MetSita/Met FDC
Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin7.65 ± 1.397.45 ± 1.48
Statistical analysis
  • Sita + Met vs Sita/Met FDC · Least-squares mean ratio: 0.97 · 90% CI 0.95 to 1.00
SecondaryPeak Plasma Concentration (Cmax) of Metformin

Serum samples were used to determine the maximum concentration for metformin.

Time frame:
Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) of Metformin
ng/mLSita + MetSita/Met FDC
Peak Plasma Concentration (Cmax) of Metformin929 ± 181887 ± 187
Statistical analysis
  • Sita + Met vs Sita/Met FDC · Least-squares mean ratio: 0.95 · 90% CI 0.93 to 0.98

Adverse events

Collected over Up to 24 days (including 14 days after administration of study drug in the last treatment period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sita + Met—0/60 (0%)2/60 (3.3%)
Sita/Met FDC—0/61 (0%)6/61 (9.8%)
Most frequent other events
Most frequent other events
EventSita + MetSita/Met FDC
HeadacheNervous system disorders2/606/61

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean32.4 (18 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female32
Male29
Height
Height(Centimeters)All Participants
Mean164.9 (150.0 to 184.0)
Weight
Weight(Kilograms)All Participants
Mean73.0 (45.9 to 102.3)
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Mar 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2009
First posted
Jun 26, 2009
Start
Jan 2008
Primary completionActual
Mar 2008
CompletionActual
May 2008
Results first posted
Feb 1, 2010
Last update
Aug 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00929201
Responsible party
Sponsor
First posted
Jun 26, 2009
Start date
Jan 2008
Primary completion
Mar 2008
Completion
May 2008
Results posted
Feb 1, 2010
Last update
Aug 13, 2015

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion